Condition: PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Metastatic Pancreas Adenocarcinoma · Sponsor: Revolution Medicines, Inc.
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.
This description comes directly from the study's public registry record.
Revolution Medicines Study Director · 1-844-2-REVMED · medinfo@revmed.com
Always discuss trial participation with your own doctor first.
| Southern Cancer Center | Daphne, Alabama, United States | Available |
| Southern Cancer Center | Mobile, Alabama, United States | Available |
| Alaska Oncology and Hematology | Anchorage, Alaska, United States | Available |
| Cancer and Blood Specialists of Arizona | Casa Grande, Arizona, United States | Available |
| Mayo Clinic - Arizona | Phoenix, Arizona, United States | Available |
| Honor Health | Scottsdale, Arizona, United States | Available |
| University of Arizona Cancer Center | Tucson, Arizona, United States | Available |
| Mercy Hospital Fort Smith | Fort Smith, Arkansas, United States | Available |
| Genesis Cancer and Blood Institute | Hot Springs, Arkansas, United States | Available |
| Care Oncology Center | Chula Vista, California, United States | Available |
| City of Hope Cancer Center (California) | Duarte, California, United States | Available |
| Cancer and Blood Specialty Clinics | Fountain Valley, California, United States | Available |
+ 158 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.